Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Inventory (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Change in Inventory data on record, last reported at -$9.0 million in Q4 2025.

  • For Q4 2025, Change in Inventory fell 136.82% year-over-year to -$9.0 million; the TTM value through Dec 2025 reached $21.1 million, down 56.84%, while the annual FY2025 figure was $21.1 million, 56.84% down from the prior year.
  • Change in Inventory reached -$9.0 million in Q4 2025 per AMPH's latest filing, down from -$5.9 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $31.1 million in Q1 2025 and bottomed at -$9.0 million in Q4 2025.
  • Average Change in Inventory over 5 years is $4.1 million, with a median of $3.4 million recorded in 2021.
  • Peak YoY movement for Change in Inventory: tumbled 309.27% in 2023, then skyrocketed 3829.48% in 2024.
  • A 5-year view of Change in Inventory shows it stood at -$7.0 million in 2021, then skyrocketed by 83.26% to -$1.2 million in 2022, then tumbled by 309.27% to -$4.8 million in 2023, then surged by 608.37% to $24.5 million in 2024, then tumbled by 136.82% to -$9.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were -$9.0 million in Q4 2025, -$5.9 million in Q3 2025, and $4.8 million in Q2 2025.